NEW YORK (Genomeweb News) – Shares of Millipore were up 4 percent at $69.02 in afternoon trade on the New York Stock Exchange after an upgrade to its rating by investment bank Leerink Swann.

The bank raised its rating on Millipore to "outperform" from "market perform." Analyst Isaac Ro said that the change was due to "improving fundamentals and execution."

Millipore "should benefit from exposure to a number of themes that include cell-based H1N1 vaccine production, an improving biologics pipeline, recent product launches, and stimulus funding," wrote Ro.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.